Download PDF
Synthesis 2001(10): 1546-1550
DOI: 10.1055/s-2001-16079
PAPER
© Georg Thieme Verlag Stuttgart · New York

Preparation of the I3 Imidazoline Receptor Antagonist KU14R and Related 2,3-Dihydrobenzo[b]furan Derivatives

J. Clewsa, Noel G. Morganb, Christopher A. Ramsden*a
a School of Chemistry and Physics, Keele University, Keele, Staffordshire ST5 5BG, UK
Fax: +44(1782)712378; e-Mail: c. a.ramsden@chem.keele.ac.uk;
b School of Life Sciences, Keele University, Keele, Staffordshire ST5 5BG, UK
Further Information

Publication History

Received 7 March 2001
Publication Date:
23 September 2004 (online)

    Permissions and Reprints All articles of this category

Abstract

The preparation and characterisation of a series of novel analogues of the imidazoline insulin secretagogue efaroxan, including the I3-receptor antagonist KU14R, are described. Replacement of the imidazoline ring of efaroxan by selected functional groups leads either to loss of activity or to very weak I3-agonist activity in insulin secretion studies. The imidazole analogue KU14R was found to be an I3-antagonist in this assay and useful as a biological tool.

Key words

imidazoline - efaroxan - I3-receptor - imidazole - antagonist - tetrazole - insulin

    References

  • 1a Molderings GJ. Drugs Future  1997,  22:  757 
    CrossrefGoogle Scholar
  • 1b Regunathan S. Reis DJ. Annu. Rev. Pharmacol. Toxicol.  1996,  36:  511 
    CrossrefGoogle Scholar
  • 2a Eglen RM. Hudson AL. Kendall DA. Nutt DJ. Morgan NG. Wilson VG. Dillon MP. Trends Pharmacol. Sci.  1998,  19:  381 
    CrossrefGoogle Scholar
  • Crossref
  • 3a Morgan NG. Exp. Opin. Invest. Drugs  1999,  8:  575 
    CrossrefGoogle Scholar
  • 3b Morgan NG. Chan SLF. Mourtada M. Monks LK. Ramsden CA. Ann. New York Acad. Sci.  1999,  881:  217 
    CrossrefGoogle Scholar
  • 4 Monks LK. Cosgrove KE. Dunne MJ. Ramsden CA. Morgan NG. Chan SLF. FEBS Letters  1999,  447:  61 
    CrossrefGoogle Scholar
  • 5a Chan SLF. Mourtada M. Morgan NG. Diabetes  2001,  50:  340 
    Google Scholar
  • 5b Zaitsev SV. Efanov AM. Efanova IB. Larsson O. Ostenson C.-G. Gold G. Berggren P.-O. Efendic S. Diabetes  1996,  45:  1610 
    Google Scholar
  • 5c

    Morgan, N. G.; Chan, S. L. F. Curr. Pharmaceut. Design 2001, in press.
  • 6a Chan SLF. Pallett AL. Clews J. Ramsden CA. Morgan NG. Eur. J. Pharmacol.  1997,  323:  241 
    Google Scholar
  • 6b Chan SLF. Atlas D. James RFL. Morgan NG. Br. J. Pharmacol.  1997,  120:  926 
    Google Scholar
  • 7 Chan SLF. Pallett AL. Clews J. Ramsden CA. Chapman JC. Kane C. Dunne MJ. Morgan NG. Eur. J. Pharmacol.  1998,  355:  67 
    CrossrefGoogle Scholar
  • 8 Edwards CR. Readhead MJ. Tweddle NJ. J. Heterocycl. Chem.  1987,  24:  495 
    Google Scholar
  • 9 Cava MP. Levinson MI. Tetrahedron  1985,  41:  5061 
    CrossrefGoogle Scholar
  • 11 Lawson A. J. Chem. Soc.  1957,  4225 
    Google Scholar
  • 12 Ramsden CA. Rose HL. J. Chem. Soc., Perkin Trans. 1  1997,  2319 
    CrossrefGoogle Scholar
  • 13 Brown CA. Chan SLF. Stillings MR. Smith SA. Morgan NG. Br. J. Pharmacol.  1993,  110:  1017 
    Google Scholar
  • 14 Kubinyi H. In Comprehensive Medicinal Chemistry   Vol. 4:  Ramsden CA. Pergamon Press; Oxford: 1990.  p.589 
    Google Scholar
  • 15 Ford RE. Knowles P. Lunt E. Marshall SM. Penrose AJ. Ramsden CA. Summers AJH. Walker JL. Wright DE. J. Med. Chem.  1986,  29:  538 
    CrossrefGoogle Scholar
10

Clews, J.; Ramsden, C. A. unpublished work.